Efficacy

Efficacy of Kadcyla (Trastuzumab Emtansine) in Breast Cancer

Kadcyla (trastuzumab emtansine) is a targeted therapy drug used for the treatment of HER2-positive breast cancer. HER2 is a protein that can promote the growth of cancer cells. In some cancers, notably breast cancer, HER2 is overexpressed, and this overexpression can be associated with increased disease aggressiveness and a poorer prognosis. Kadcyla is designed to target and destroy the cancer cells that have HER2 on their surface. It is typically used in patients who have previously received trastuzumab and a taxane, separately or in combination. Clinical trials have demonstrated that Kadcyla significantly improves progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer compared to standard therapies.

The efficacy of Kadcyla was highlighted in a pivotal phase III clinical trial known as EMILIA. The trial compared Kadcyla to lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer who had previously been treated with trastuzumab and a taxane chemotherapy. The results showed that Kadcyla significantly extended median progression-free survival and overall survival. These findings established Kadcyla as an effective treatment option for patients with this type of breast cancer, particularly in the metastatic setting.

Efficacy of Orserdu (Elacestrant) in Breast Cancer

Orserdu (elacestrant) is a novel oral selective estrogen receptor degrader (SERD) that is being investigated for the treatment of estrogen receptor (ER)-positive breast cancer. ER-positive breast cancer is the most common subtype of breast cancer, where the cancer cells grow in response to the hormone estrogen. Orserdu works by binding to the estrogen receptor, degrading it, and thus inhibiting the receptor's interaction with estrogen. This mechanism can help to slow or stop the growth of ER-positive breast cancer cells.

While Orserdu is still under clinical investigation, early trial results have been promising. In a phase II study, Orserdu showed clinical efficacy in patients with ER-positive, HER2-negative advanced breast cancer who had progressed on prior endocrine therapy and CDK4/6 inhibitors. The study indicated that Orserdu has the potential to be an effective treatment option for this patient population, which often has limited treatment choices after standard therapies fail. As research continues, Orserdu may offer a new hope for patients with ER-positive breast cancer, particularly those with advanced or metastatic disease.